circadian rhythm is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
=== MeSH D12.644.641 – peptides, cyclic === MeSH D12.644.641.040 – alamethicin MeSH D12.644.641.050 – amanitins MeSH D12.644.641.075 – bacitracin MeSH D12.644.641.142 – capreomycin sulfate MeSH D12.644.641.235 – cyclosporins MeSH D12.644.641.235.300 – cyclosporine MeSH D12.644.641.243 – cyclotides MeSH D12.644.641.252 – dactinomycin MeSH D12.644.641.270 – daptomycin MeSH D12.644.641.297 – depsipeptides MeSH D12.644.641.297.500 – valinomycin MeSH D12.644.641.325 – echinomycin MeSH D12.644.641.380 – ferrichrome MeSH D12.644.641.515 – mycobacillin MeSH D12.644.641.548 – nanotubes, peptide MeSH D12.644.641.582 – nisin MeSH D12.644.641.650 – octreotide MeSH D12.644.641.735 – phalloidine MeSH D12.644.641.780 – polymyxins MeSH D12.644.641.780.110 – colistin MeSH D12.644.641.780.750 – polymyxin b MeSH D12.644.641.802 – streptogramins MeSH D12.644.641.802.249 – mikamycin MeSH D12.644.641.802.374 – pristinamycin MeSH D12.644.641.802.500 – streptogramin group a MeSH D12.644.641.802.500.500 – streptogramin a MeSH D12.644.641.802.750 – streptogramin group b MeSH D12.644.641.802.750.500 – streptogramin b MeSH D12.644.641.802.812 – vernamycin b MeSH D12.644.641.802.875 – virginiamycin MeSH D12.644.641.802.875.500 – streptogramin a MeSH D12.644.641.825 – thiostrepton MeSH D12.644.641.875 – viomycin MeSH D12.644.641.875.250 – enviomycin
== Adverse effects == A 2010 Cochrane review of finasteride for BPH found that, in men with a weighted mean age of 62.4, adverse effects are rare in men with already enlarged prostates; "nevertheless, men taking finasteride are at increased risk for impotence, erectile dysfunction, decreased libido, and ejaculation disorder, versus placebo." As of 2016, fresh evidence suggested such effects, along with disturbed neurosteroid production, may persist after finasteride use is stopped. Finasteride is contraindicated in pregnancy. The US Food and Drug Administration (FDA) advises that donation of blood or plasma be deferred for at least one month after taking the last dose of finasteride. The FDA has added a warning to 5α-reductase inhibitors concerning an increased risk of high-grade prostate cancer, as the treatment of BPH lowers PSA (prostate-specific antigen), which could mask the development of prostate cancer. Although overall incidence of male breast cancer in clinical trials for finasteride 5 mg was not increased, there are post-marketing reports of breast cancer in association with its use, though available evidence does not provide clarity as to whether there is a causative relationship between finasteride and these cancers. A 2018 meta-analysis found no higher risk of breast cancer with 5α-reductase inhibitors. Some men develop gynecomastia (breast development or enlargement) following finasteride usage. The risk of gynecomastia with 5α-reductase inhibitors is low at about 1.5%. Depressive symptoms and suicidality have been reported.
The FDA has identified that breast implants may be associated with a rare form of cancer called anaplastic large-cell lymphoma (ALCL), which some experts believe is believed to be associated with chronic bacterial inflammation. Similar ALCL phenomena have been seen with other types of medical implants including vascular access ports, orthopedic hip implants, and jaw (TMJ) implants. The causal association between breast implants and ALCL was conclusively established in December 2013, when researchers at MD Anderson Cancer Center published a study of 60 women with breast implants who were diagnosed with ALCL in the breast. In 2015, plastic surgeons published an article reviewing 37 articles in the literature on 79 patients and collected another 94 unreported cases, resulting in 173 women with breast implants who had developed ALCL of the breast. They concluded that "Breast implant-associated ALCL is a novel manifestation of site- and material-specific lymphoma originating in a specific scar location, presenting a wide array of diverse characteristics and suggesting a multifactorial cause." They stated that "There was no preference for saline or silicone fill or for cosmetic or reconstructive indications." Where implant history was known, the patient had received at least one textured-surface device. In 2016, the World Health Organization (WHO) officially recognized BIA-ALCL. As of April 2022, the FDA has received 1,130 global medical device reports (MDRs) of BIA-ALCL, including 59 deaths.
The light source is shone into the sample and focused into a slit The transmitted light is refracted into a rainbow with the reflection grating The resulting light strikes the photodetector device which compares the intensity of the beam Electronic circuits convert the relative currents into linear transmission percentages and/or absorbance/concentration values Many older spectrophotometers must be calibrated by a procedure known as "zeroing", to balance the null current output of the two beams at the detector. The transmission of a reference substance is set as a baseline (datum) value, so the transmission of all other substances is recorded relative to the initial "zeroed" substance. The spectrophotometer then converts the transmission ratio into 'absorbency', the concentration of specific components of the test sample relative to the initial substance.
=== Perrault method === This approach, discovered by Perrault and Chan in 2009, uses hydroquinone to reduce HAuCl4 in an aqueous solution that contains 15 nm gold nanoparticle seeds. This seed-based method of synthesis is similar to that used in photographic film development, in which silver grains within the film grow through addition of reduced silver onto their surface. Likewise, gold nanoparticles can act in conjunction with hydroquinone to catalyze reduction of ionic gold onto their surface. The presence of a stabilizer such as citrate results in controlled deposition of gold atoms onto the particles, and growth. Typically, the nanoparticle seeds are produced using the citrate method. The hydroquinone method complements that of Frens, as it extends the range of monodispersed spherical particle sizes that can be produced. Whereas the Frens method is ideal for particles of 12–20 nm, the hydroquinone method can produce particles of at least 30–300 nm.
Sources: en.wikipedia.org
The peculiarity of this invention compared to former treatment approaches for treating sleep disorders is the so far unknown therapeutic efficacy of (R)-phenylpiracetam, which is presumably based at least in part on the newly identified activity of (R)-phenylpiracetam as the dopamine re-uptake inhibitor Both enantiomers of phenylpiracetam, (R)-phenylpiracetam and (S)-phenylpiracetam, have been described in peer-reviewed research as dopamine transporter (DAT) inhibitors in rodents, confirming the patent claim. Their actions at the norepinephrine transporter (NET) vary: (R)-phenylpiracetam acts as a dual norepinephrine–dopamine reuptake inhibitor (NDRI), with 11-fold lower affinity for the NET than for the DAT, whereas the (S)-enantiomer is selective for the DAT. However, whereas (R)-phenylpiracetam stimulates locomotor activity, (S)-phenylpiracetam does not do so. This kind of variation in effects has also been seen with other dopamine reuptake inhibitors. Other atypical dopamine reuptake inhibitors include modafinil, mesocarb (Sydnocarb), and solriamfetol.
== 2018 suicide attempt and introduction to DMT == On January 15, 2018, Cantelmo contacted his children and told them he intended to kill himself. Police placed him on a 5150 hold, an involuntary psychiatric detention. While in the facility he decided to try DMT after his release. After leaving the hospital he ordered mimosa hostilis root bark online, extracted DMT using methods based on his chemistry background, and began experimenting with the substance. He later described a breakthrough experience that ended his lifelong atheism and convinced him of the existence of a higher power and of entities he encountered during the trips. He resolved to promote DMT publicly.
=== Position of Tantulocarida === According to Petrunina A.S. and Kolbasov G.A., the sixth subclass of Maxillopoda Tantulocarida may lie within Thecostraca, forming a clade with thecostracan infraclass Cirripedia (if so, Thecostraca excluding Tantulocarida is paraphyletic):
== Fissile vs fissionable == The term fissile is distinct from fissionable. A nuclide that can undergo nuclear fission (even with a low probability) after capturing a neutron of high or low energy is referred to as fissionable. A fissionable nuclide that can undergo fission with a high probability after capturing a low-energy thermal neutron is referred to as fissile. Fissionable materials include those (such as uranium-238) for which fission can be induced only by high-energy neutrons. As a result, fissile materials (such as uranium-235) are a subset of fissionable materials.
Sources: en.wikipedia.org
== Overview == A sequence begins with a greater-than character (">") followed by a description of the sequence (all in a single line). The lines immediately following the description line are the sequence representation, with one letter per amino acid or nucleic acid, and are typically no more than 80 characters in length. For example:
=== 2012 === On February 23, 2012, NHK announced that with Shizuoka University they had developed an 8K sensor that can shoot video at 120 fps. In April 2012, Panasonic, in collaboration with NHK announced a 145 inches (370 cm) display (7680 × 4320 at 60 fps), which has 33.2 million 0.417 mm square pixels. In April 2012, the four major South Korean terrestrial broadcasters (KBS, MBC, SBS, and EBS) announced that in the future, they would begin test broadcasts of UHDTV on channel 66 in Seoul. At the time of the announcement, the UHDTV technical details had not yet been decided. LG Electronics and Samsung are also involved in UHDTV test broadcasts. In May 2012, NHK showed the world's first ultra-high-definition shoulder-mount camera. By reducing the size and weight of the camera, the portability had been improved, making it more maneuverable than previous prototypes, so it could be used in a wide variety of shooting situations. The single-chip sensor uses a Bayer color-filter array, where only one color component is acquired per pixel. Researchers at NHK also developed a high-quality up-converter, which estimates the other two color components to convert the output into full resolution video. Also in May 2012, NHK showed the ultra-high-definition imaging system it has developed in conjunction with Shizuoka University, which outputs 33.2-megapixel video at 120 fps with a color depth of 12 bits per component.
== Design == Adam Foster, Minerva's designer, is critical of Valve's design of Half-Life 2 maps. His belief is that game developers focus on creating gameplay friendly environments that do not work in an architectural way, "a series of unconnected boxes" says Foster, Minerva's environments are built as actual environments (with correctly proportioned structures and areas) with gameplay worked in later. This creates a more open design, in which players may, in places, navigate in multiple ways. Later locations can be seen in earlier stages of the game (along corridors or through windows for example). Map design is the mod's hallmark. While all levels are constructed primarily using Valve's resources, with few new models or textures, Foster follows his own design ideals – that of compact, well designed maps. Although the levels seem huge, as play unfolds, they are in fact very small - wrapping around to use the least space possible. This creates a sense of realism. As pointed out by Planet Half-Life: "Instead of relying on horizontally-sprawling, immense maps that stress the engine's area-capabilities to its max, Minerva maps are incredibly small. This is because of Foster's ground-breaking idea to utilize every possible area to its maximum potential, and instead of expanding horizontally, he expands vertically." As a result, Minerva maps have a much shorter load time than maps in the original game. Foster creates the maps in layers.
As a result, currant growing is making a comeback in New York, Vermont, Connecticut, California, and Oregon. However, several statewide bans still exist as of August 2021. Since the American federal ban curtailed currant production nationally for nearly a century, the fruit remains largely unknown in the United States and has yet to regain its previous popularity to levels enjoyed in Europe or New Zealand. Owing to its unique flavour and richness in polyphenols, dietary fibre and essential nutrients, awareness and popularity of blackcurrant is once again growing, with a number of consumer products entering the U.S. market.
== Toxicological data == The toxicological effects of 2,6‑dichloro‑1,4‑benzoquinone (2,6‑DCBQ) have been investigated in several experimental models. In mice, a 28‑day exposure study reported renal injury following 2,6‑DCBQ exposure. Proposed mechanisms include the activation of inflammatory pathways, oxidative stress, and apoptosis. Toxicity has also been examined in embryonic zebrafish, where exposure resulted in acute and developmental toxicity. Observed effects included impaired cardiovascular development and alterations in molecular signaling pathways. Studies using human cell lines have also reported cytotoxic effects. In kidney cells, exposure primarily induces anoikis, a form of apoptosis associated with loss of cell–matrix interactions. In human colon epithelial and liver cells, 2,6‑DCBQ exposure increases the production of reactive oxygen species (ROS). Prolonged low‑dose exposure in normal colon and liver cell lines has been associated with oxidative stress, DNA damage, and molecular changes that may indicate a potential role in carcinogenesis. In cell culture systems, the half‑life of 2,6‑DCBQ has been estimated to be less than one hour, and the parent compound appears to exhibit greater cytotoxicity than its transformation product.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.